Table 2.
Gene | Variant | Function | Rate | Ref. |
---|---|---|---|---|
NOTCH1 | Mutation | Activation (T-ALL) | 60% | [54] |
NOTCH1 | Mutation | Response to GSI and prognosis (NSCLC) | 12% | [55] |
NOTCH2 | Mutation | Unknown (Breast Cancer) | 2.1% | [57] |
NOTCH3 | Mutation | Unknown(Colorectal Cancer) | 2% | [57] |
NOTCH3 | Amplification | Response to GSI (Ovarian Cancer) | 19.5% | [56] |
NOTCH2 | SNP | Increased cancer risk (Breast Cancer) | 16.8% | [58] |
HEY1 | SNP | Response to p53 activators | 1% | [59] |
We selected both single nucleotide polymorphisms (SNP) and somatic alterations (gene amplifications, mutations) affecting cancer cell behavior. Rate refers to mutation rate in cancer samples, or minor allele frequency in Caucasians (SNP). T-ALL, T-cell acute lymphoid leukemia; NSCLC, non-small cell lung cancer; GSI, γ-secretase inhibitor.